The aneuploidy paradox: Costs and benefits of an incorrect karyotype

Trends in Genetics

Volumn 27, Issue 11, 2011, Pages 446-453

  Sheltzer, Jason M ^a   Amon, Angelika ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE MARKER; EVOLUTION; HUMAN; KARYOTYPE; MICROORGANISM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANEUPLOIDY; CELL PROLIFERATION; COST-BENEFIT ANALYSIS; DIAGNOSTIC ERRORS; GENETIC DISEASES, INBORN; GENETIC FITNESS; HUMANS; KARYOTYPE; KARYOTYPING; MODELS, BIOLOGICAL;

EID: 80054054260     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2011.07.003     Document Type: Review

References (109)

1. Hardy P.A., Zacharias H. Reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol. Int. 2005, 29:983-992.
2. Schvartzman J.-M., et al. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer 2010, 10:102-115.
3. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 2007, 8:379-393.
4. Storchova Z., Kuffer C. The consequences of tetraploidy and aneuploidy. J. Cell Sci. 2008, 121:3859-3866.
5. Lee H.O., et al. Endoreplication: polyploidy with purpose. Genes Dev. 2009, 23:2461-2477.
6. Hassold T., et al. Human aneuploidy: Incidence, origin, and etiology. Environ. Mol. Mutagen. 1996, 28:167-175.
7. Brown S. Miscarriage and its associations. Semin. Reprod. Med. 2008, 26:391-400.
8. Pai G.S., et al. Handbook of Chromosomal Syndromes 2002, Wiley-Liss. 1st edn.
9. Epstein C.J. Mouse monosomies and trisomies as experimental systems for studying mammalian aneuploidy. Trends Genet. 1985, 1:129-134.
10. McClintock B. A cytological and genetical study of triploid maize. Genetics 1929, 14:180-222.
11. Lindsley D.L., et al. Segmental aneuploidy and the genetic gross structure of the Drosophila genome. Genetics 1972, 71:157-184.
12. Hodgkin J. X chromosome dosage and gene expression in Caenorhabditis elegans: two unusual dumpy genes. Mol. Gen. Genet. 1983, 192:452-458.
13. Hodgkin J., et al. Nondisjunction mutants of the nematode Caenorhabditis elegans. Genetics. 1979, 91:67-94.
14. Sigurdson D.C., et al. An X-autosome fusion chromosome of Caenorhabditis elegans. Mol. Gen. Genet. 1986, 202:212-218.
15. Rehen S.K., et al. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13361-13366.
16. Yurov Y.B., et al. Aneuploidy and confined chromosomal mosaicism in the developing human brain. PLoS ONE 2007, 2:e558.
17. Gupta S. Hepatic polyploidy and liver growth control. Semin. Cancer Biol. 2000, 10:161-171.
18. Duncan A.W., et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature 2010, 467:707-710.
19. Kingsbury M.A., et al. Aneuploid neurons are functionally active and integrated into brain circuitry. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:6143-6147.
20. Iourov I.Y., et al. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol. Dis. 2009, 34:212-220.
21. Iourov I.Y., et al. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum. Mol. Genet. 2009, 18:2656-2669.
22. Herbst E.W., Winking H. Adoptive transfer of the hematopoietic system of trisomic mice with limited life span: stem cells from six different trisomies are capable of survival. Dev. Genet. 1991, 12:415-422.
23. Segal D.J., McCoy E.E. Studies on Down's syndrome in tissue culture. I. Growth rates protein contents of fibroblast cultures. J. Cell. Physiol. 1974, 83:85-90.
24. Kops G.J.P.L., et al. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8699-8704.
25. Babu J.R., et al. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J. Cell Biol. 2003, 160:341-353.
26. Li M., et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14188-14193.
27. Weaver B.A.A., et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007, 11:25-36.
28. Baker D.J., et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat. Genet. 2004, 36:744-749.
29. van Ree J.H., et al. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J. Cell Biol. 2010, 188:83-100.
30. Thompson S.L., Compton D.A. Examining the link between chromosomal instability and aneuploidy in human cells. J. Cell Biol. 2008, 180:665-672.
31. Thompson S.L., Compton D.A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J. Cell Biol. 2010, 188:369-381.
32. Torres E.M., et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007, 317:916-924.
33. Pavelka N., et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 2010, 468:321-325.
34. Niwa O., Yanagida M. Triploid meiosis and aneuploidy in Schizosaccharomyces pombe: an unstable aneuploid disomic for chromosome III. Curr. Genet. 1985, 9:463-470.
35. Niwa O., et al. Growth arrest and chromosome instability in aneuploid yeast. Yeast 2006, 23:937-950.
36. Williams B.R., et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008, 322:703-709.
37. Futcher B., Carbon J. Toxic effects of excess cloned centromeres. Mol. Cell. Biol. 1986, 6:2213-2222.
38. Runge K.W., Zakian V.A. Introduction of extra telomeric DNA sequences into Saccharomyces cerevisiae results in telomere elongation. Mol. Cell. Biol. 1989, 9:1488-1497.
39. Mao R., et al. Global up-regulation of chromosome 21 gene expression in the developing down syndrome brain. Genomics 2003, 81:457-467.
40. FitzPatrick D.R., et al. Transcriptome analysis of human autosomal trisomy. Hum. Mol. Genet. 2002, 11:3249-3256.
41. Huettel B., et al. Effects of aneuploidy on genome structure, expression, and interphase organization in Arabidopsis thaliana. PLoS Genet. 2008, 4:e1000226.
42. Rancati G., et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell 2008, 135:879-893.
43. Hughes T.R., et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat. Genet. 2000, 25:333-337.
44. Torres E.M., et al. Identification of aneuploidy-tolerating mutations. Cell 2010, 143:71-78.
45. Torres E.M., et al. Aneuploidy: cells losing their balance. Genetics 2008, 179:737-746.
46. Katz W., et al. Regulation of tubulin levels and microtubule assembly in Saccharomyces cerevisiae: consequences of altered tubulin gene copy number. Mol. Cell. Biol. 1990, 10:5286-5294.
47. Hasle H., et al. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
48. Baek K.-H., et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
49. Sussan T.E., et al. Trisomy represses ApcMin-mediated tumours in mouse models of Down's syndrome. Nature 2008, 451:73-75.
50. Kaeberlein M., et al. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999, 13:2570-2580.
51. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
52. Ibáñez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
53. Devlin R.H., et al. Autosomal dosage compensation Drosophila melanogaster strains trisomic for the left arm of chromosome 2. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:1200-1204.
54. McAnally A.A., Yampolsky L.Y. Widespread transcriptional autosomal dosage compensation in Drosophila correlates with gene expression level. Genome Biol. Evol. 2010, 2:44-52.
55. Papp B., et al. Dosage sensitivity and the evolution of gene families in yeast. Nature 2003, 424:194-197.
56. Kaizu K., et al. Fragilities caused by dosage imbalance in regulation of the budding yeast cell cycle. PLoS Genet. 2010, 6:e1000919.
57. Vavouri T., et al. Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell 2009, 138:198-208.
58. Pavelka N., et al. Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr. Opin. Cell Biol. 2010, 22:809-815.
59. Bean J., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20932-20937.
60. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
61. Tang Y.-C., et al. Identification of aneuploidy-selective antiproliferation compounds. Cell 2011, 144:499-512.
62. Siegers K., et al. TRiC/CCT cooperates with different upstream chaperones in the folding of distinct protein classes. EMBO J. 2003, 22:5230-5240.
63. Geiler-Samerotte K.A., et al. Misfolded proteins impose a dosage-dependent fitness cost and trigger a cytosolic unfolded protein response in yeast. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:680-685.
64. Gunjan A., Verreault A. A Rad53 kinase-dependent surveillance mechanism that regulates histone protein levels in S. cerevisiae. Cell 2003, 115:537-549.
65. Abovich N., et al. Effect of RP51 gene dosage alterations on ribosome synthesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 1985, 5:3429-3435.
66. Warner J.R., et al. Saccharomyces cerevisiae coordinates accumulation of yeast ribosomal proteins by modulating mRNA splicing, translational initiation, and protein turnover. Mol. Cell. Biol. 1985, 5:1512-1521.
67. Vander Heiden M.G., et al. Understanding the Warburg Effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
68. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
69. Weaver B.A., Cleveland D.W. Does aneuploidy cause cancer?. Curr. Opin. Cell Biol. 2006, 18:658-667.
70. Balaban G.B., et al. Karyotypic evolution in human malignant melanoma. Cancer Genet. Cytogenet. 1986, 19:113-122.
71. Heselmeyer-Haddad K., et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am. J. Pathol. 2005, 166:1229-1238.
72. Rubin C.E., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103:1611-1620.
73. Conti C.J., et al. Aneuploidy, an early event in mouse skin tumor development. Carcinogenesis 1986, 7:1845-1848.
74. Danielsen H.E., et al. Specific gain of chromosome 19 in preneoplastic mouse liver cells after diethylnitrosamine treatment. Carcinogenesis 1991, 12:1777-1780.
75. Barber T.D., et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3443-3448.
76. Cahill D.P., et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303.
77. Sotillo R., et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 2007, 11:9-23.
78. Hanks S., et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 2004, 36:1159-1161.
79. Baker D.J., et al. Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell. 2009, 16:475-486.
80. Dunham M.J., et al. Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16144-16149.
81. Gresham D., et al. The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. PLoS Genet. 2008, 4:e1000303.
82. Selmecki A., et al. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006, 313:367-370.
83. Selmecki A., et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 2008, 68:624-641.
84. Cao Y., et al. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci. 2008, 99:1092-1099.
85. Kibbelaar R.E., et al. Detection of trisomy 8 in hematological disorders by in situ hybridization. Cytogenet. Cell Genet. 1991, 56:132-136.
86. Oudat R., et al. Detection of Trisomy 8 in Philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc Involvement. Ann. Clin. Lab. Sci. 2001, 31:68-74.
87. Soder A.I., et al. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997, 14:1013-1021.
88. Yokoi S., et al. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin. Cancer Res. 2003, 9:4705-4713.
89. Jennings B.A., Mills K.I. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk. Res. 1998, 22:899-903.
90. La Farina M., et al. Two distinct amplification events of the c-myc locus in a colorectal tumour. J. Cell. Physiol. 2008, 217:34-39.
91. Baker D.J., van Deursen J.M. Chromosome missegregation causes colon cancer by APC loss of heterozygosity. Cell Cycle 2010, 9:1711-1716.
92. Beroukhim R., et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput. Biol. 2006, 2:e41.
93. Gondek L.P., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
94. Holliday R. Chromosome error propagation and cancer. Trends Genet. 1989, 5:42-45.
95. Matzke M. Does the intrinsic instability of aneuploid genomes have a causal role in cancer?. Trends Genet. 2003, 19:253-256.
96. Sheltzer J., et al. Aneuploidy drives genomic instability in yeast. Science 2011, 333:1026-1030.
97. Duesberg P., et al. Genetic instability of cancer cells is proportional to their degree of aneuploidy. PNAS 1998, 95:13692-13697.
98. Lambert B., et al. DNA repair and frequency of X-ray and u.v-light induced chromosome aberrations in leukocytes from patients with Down's syndrome. Ann. Hum. Genet. 1976, 39:293-303.
99. Iijima K., et al. Bleomycin-induced chromosomal aberrations and sister chromatid exchanges in Down lymphocyte cultures. Hum. Genet. 1984, 66:57-61.
100. Otsuka F., et al. Hypersensitivity to ionizing radiation in cultured cells from down syndrome patients. J. Neurol. Sci. 1985, 69:103-112.
101. Shafik H.M., et al. Chromosomal radiosensitivity of Down syndrome lymphocytes at different stages of the cell cycle. Hum. Genet. 1988, 78:71-75.
102. Cahill D.P., et al. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999, 9:M57-M60.
103. Thompson D.A., et al. Ploidy controls the success of mutators and nature of mutations during budding yeast evolution. Curr. Biol. 2006, 16:1581-1590.
104. Sniegowski P.D., et al. Evolution of high mutation rates in experimental populations of E. coli. Nature 1997, 387:703-705.
105. Giraud A., et al. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 2001, 291:2606-2608.
106. Lengauer C., et al. Genetic instability in colorectal cancers. Nature 1997, 386:623-627.
107. Bielas J.H., et al. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18238-18242.
108. Lengauer C., et al. Genetic instabilities in human cancers. Nature 1998, 396:643-649.
109. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010, 31:955-960.